SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following its earnings report and subsequent guidance, which triggered a significant sell-off. The community is sharply divided, with many expressing disappointment over perceived management communication issues and competitive pressures, while others believe strong underlying demand makes this an attractive buying opportunity. The broader discussion includes the impact of government backing and Intel's long-term foundry ambitions.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune Inc. is currently trending as community excitement builds around its pemvidutide program, recently granted Breakthrough Therapy Designation by the FDA for MASH. Investors are actively discussing the drug's 'best-in-class' profile and its potential as an acquisition target or partnership deal in the rapidly expanding MASH and obesity markets. Many believe the company is significantly undervalued given these developments, anticipating a major rerating or buyout as key catalysts.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp is trending due to its pivotal role in post-quantum cryptography and hardware-rooted security, underscored by a significant Memorandum of Understanding to establish a semiconductor center in India and recent presentations at the World Economic Forum. The community is actively discussing the company's crucial position within the "Age of Convergence" for AI, quantum computing, and IoT, highlighting its perceived undervaluation and potential for a short squeeze amidst growing demand for quantum-resistant solutions.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies (ASTI) is experiencing a surge of attention, primarily driven by Elon Musk's comments on the critical role of lightweight, flexible solar technology for future space-based AI data centers, a niche where ASTI holds existing expertise and strategic partnerships. The community is buzzing with speculation about a potential short squeeze and a multi-day rally, fueled by the stock's low float and high short interest, though some caution remains regarding its historical volatility and potential for dilution.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is actively trending following its selection as the official air taxi partner for EXPO 2027 in Serbia and a strategic partnership with NVIDIA to integrate advanced AI technology into its Midnight eVTOL aircraft. The community is buzzing with anticipation for FAA certification progress and piloted flight updates, which many believe will finally propel the stock past its recent consolidation and unlock its substantial order book and long-term potential in the emerging air mobility market.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is drawing significant attention ahead of its anticipated Q4 earnings, with investors closely watching for insights into potential margin improvements from new pricing models versus ongoing concerns about rising medical costs. Community discussions are highly focused on the company's announced plan to rebate ACA profits, a strategic move many believe is aimed at enhancing public perception amidst an evolving political landscape and increasing scrutiny on healthcare affordability.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is trending due to intense speculation around a potential short squeeze, fueled by its extremely low public float. The community is highly polarized, with aggressive bullish calls for a significant price surge contrasting sharply with warnings of a 'pump and dump' and references to the company's ongoing strategic review, discontinued clinical trials, and reduced operations. This dynamic reflects the high-risk, high-reward nature often associated with micro-cap biotech plays undergoing significant structural changes.

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.

60 Degrees Pharmaceuticals Inc

60 Degrees Pharmaceuticals (SXTP) is trending following news of a partnership with Runway Health, offering direct telehealth access to its FDA-approved malaria prevention drug, ARAKODA, for international travelers. This announcement has fueled intense community discussion, with many speculating on short squeeze potential due to the stock's low float and comparing it to other high-volatility micro-caps. However, significant skepticism remains regarding potential dilution and the company's financial health, creating a divided outlook among traders.

BitGo Holdings, Inc. provides cryptocurrency custody solutions. It offers self-custody wallet, qualified custody, liquidity and prime, and infrastructure-as-a-service. The company was founded by Michael Belshe in 2013 and is headquartered in Palo Alto, CA.

BitGo Holdings Inc. - Ordinary Shares - Class A

BitGo Holdings is trending following its highly anticipated IPO as the first crypto company to list publicly in 2026, opening above its offering price. The community is actively discussing its unique position as a pure-play institutional crypto custodian, highlighting its regulatory moat and small share float as key factors that could drive significant price appreciation, despite some initial trading volatility.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending following news of a finalized deal for a TikTok US joint venture, which positions Oracle with an equity stake and responsibility for hosting the app's crucial US user data on its cloud infrastructure. Community perspectives are polarized; many foresee substantial benefits from this strategic partnership, while a vocal segment remains skeptical, citing concerns over the company's debt and the possibility of a "sell the news" reaction. This deal further solidifies Oracle's expanding role in the competitive cloud and AI infrastructure landscape, particularly within regulated sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nuwellis, Inc. Profit Declines In Q3

(RTTNews) - Nuwellis, Inc. (NUWE) announced earnings for third quarter that Dropped, from last year...

Nuwellis shares rose in after-hours trading after the company said it was granted a new U.S. Patent for innovations in blood filtering machine design and methods that improve fluid management accuracy during ultrafiltration therapy.At the close on Tuesday, <a href="https://stocktwits.com/symbol/NUWE">Nuwellis shares</a> dropped 11.7% to $6.9, but surged 31.3% to $9.05 in after-hours trading following news of the patent grant.The patent, titled “Extracorporeal Blood Filtering Machine and Methods”, addresses a critical source of error in continuous renal replacement therapy (CRRT) by factoring in actual fluid density, rather than assuming a standard value.&nbsp;Most current systems use 1 g/mL as&nbsp;the&nbsp;default, which can lead to miscalculations in fluid balance when actual densities differ.&nbsp;The new approach allows machines to adjust calculations based on input, measurement, or derived values, improving volumetric flow tracking and patient care.The company,&nbsp;based in Minneapolis with operations in Ireland,&nbsp;markets the Aquadex SmartFlow system for ultrafiltration and is&nbsp;The patent comes on the heels of two other major corporate developments in recent months.&nbsp;In June, Nuwellis raised $4.3 million through an underwritten public offering that included common stock and warrants. The company said the proceeds would go toward working capital, general corporate purposes, and potential acquisitions.In May, Nuwellis finalized a manufacturing agreement with KDI Precision Manufacturing, transferring assembly responsibilities for its Aquadex SmartFlow console and related products.&nbsp;The partnership&nbsp;aims to expand manufacturing capacity and enhance operational efficiency, with KDI also hiring current Nuwellis assembly employees to ensure a seamless transition.On Stocktwits, retail sentiment for Nuwellis was ‘extremely bullish’ by late Tuesday, improving from the ‘bullish’ mood a day ago, amid ‘extremely high’ message volume.One user said that a back-to-back spike within 24 hours typically signals that a larger move is underway.&nbsp;<stembedurl>https://stocktwits.com/Enjoiskating1216/message/621091545</stembedurl>Another expressed confidence in a major upside, suggesting the stock could revisit the $50 mark.<stembedurl>https://stocktwits.com/BestNwest/message/621099818</stembedurl>Nuwellis’ stock has declined 86.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nuwellis (NUWE) was granted a new U.S. Patent for innovations in blood filtering machine design. (Photo credit: Getty Images)

Nuwellis Stock Rises After Hours Following Patent Win For Blood Filtering System — Retail Mood Turns Buoyant

The patent for its blood filtering technology aims to improve fluid balance accuracy in CRRT by accounting for actual fluid density instead of relying on standard assumptions.

Equity

Nuwellis, Inc. (NUWE) Reports Q1 Loss, Lags Revenue Estimates

CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates

Shares of medical device company Nuwellis Inc. ($NUWE) more than doubled on Monday afternoon following its announcement that the Centers for Medicare and Medicaid Services (CMS) will significantly hike the reimbursement levels for its ultrafiltration therapy, lifting retail sentiment. Effective January 1, 2025, the reimbursement payment rate for the Minneapolis-based company’s Aquadex SmartFlow therapy, used for treating fluid overload in heart failure patients, will increase from $413 to $1,639 per day, a major step for the company’s outpatient therapy.&nbsp; Stocktwits users celebrated the move, suggesting the stock should go much higher following the news.&nbsp; &nbsp;<stembedurl>https://stocktwits.com/xpb199/message/591140624</stembedurl><stembedurl>https://stocktwits.com/Rampageusa/message/591116254</stembedurl> &nbsp;"This change underscores the clinical importance and cost-effectiveness of our ultrafiltration technology and will expand patient access to this life-saving therapy,” Nestor Jaramillo, President and CEO of Nuwellis, said in a statement. “It is well understood that providing care in an outpatient setting can be a better means to manage disease and prevent costly emergency hospitalizations.”&nbsp; The move will help expand the therapy’s reach to more patients on the sub-acute or chronic disease management program.Nuvellis plans to report its <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketwatch.com/story/nuwellis-shares-surge-following-preliminary-3q-results-c5fa917d">third-quarter</a> results and host its earnings conference call on November 11. The company said recently it is expecting to report revenue of $2.4 million, in line with the year-ago period.Nuwellis shares rallied over 106% today, but the stock is down roughly 88% year-to-date. Still, the stock is seeing a major jump in activity among retail investors and traders, with today’s symbol page views on Stocktwits hitting more than 25x their average over their one-month average.For updates and corrections, email newsroom@stocktwits.com

Shares of medical device company Nuwellis Inc. ($NUWE) more than doubled on Monday afternoon| Image source: Pixabay

Nuwellis Stock Spikes After Reimbursement Hike: Retail’s Upbeat

Effective January 1, 2025, the payment rate for its Aquadex SmartFlow therapy, used for treating fluid overload in heart failure patients, will increase 397% from $413 to $1,639 per day.

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Nuwellis Inc

Policy uncertainty from Trump

Earnings & guidance

Options / dealer positioning

Liquidity & algos

Markets are reacting to a mix of policy headlines, earnings, and positioning. We want to hear what you think is driving volatility the most right now.

What&#39;s the biggest driver of market volatility right now?

Stocktwits

What's the biggest driver of market volatility right now?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.56	--	--	N/A
Q3 '25	--	$0.56	--	N/A
Q2 '25	-$18.90	-$60.99	-222.70%	MISSED
Q1 '25	-$0.45	-$28.98	-6340.00%	MISSED
Q4 '24	-$0.43	-$0.44	-2.33%	MISSED

NUWE
Nuwellis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest NUWE News

NUWENuwellis Inc